Welcome to our dedicated page for Concord Medical news (Ticker: CCM), a resource for investors and traders seeking the latest updates and insights on Concord Medical stock.
Concord Medical Services Holdings Limited reports developments as a China-based oncology healthcare provider focused on cancer diagnosis, treatment, research, education and prevention. Its updates center on self-owned cancer hospitals and clinics, partnered hospitals, and oncology service lines that include radiotherapy, diagnostic imaging, hospital operations and premium cancer care.
Recurring news covers financial results for the hospital and network businesses, annual reports on Form 20-F, shareholder meetings, and governance actions. Company and subsidiary announcements also address Concord Healthcare Group, its Hong Kong-listed H shares, proton therapy operations at Guangzhou Concord Cancer Hospital, medical-device approvals tied to proton equipment, treatment milestones, and oncology technology such as a proton therapy large language model.
Concord Medical Services Holdings (NYSE: CCM) has announced that its subsidiary, Guangzhou Concord Cancer Center, has obtained a large medical equipment procurement license for its proton therapy equipment. This development follows the completion of equipment installation in September 2020 and the commencement of clinical trials in November 2022. The license, granted by the National Health Commission of the PRC on September 14, 2024, allows Guangzhou Hospital to offer proton therapy treatment services.
Additionally, Concord Healthcare Group Co., , a subsidiary of Concord Medical listed on the Hong Kong Stock Exchange (2453.HK), made a similar announcement on September 15, 2024. This news marks a significant step for Concord Medical in expanding its cancer treatment services in China.
Concord Medical Services Holdings (NYSE: CCM), a Chinese healthcare provider specializing in cancer treatment, research, education, and prevention, has regained compliance with the New York Stock Exchange's (NYSE) minimum price requirement. The company received a Compliance Notice on August 6, 2024, confirming that it is no longer below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period.
This development follows a previous notification from the NYSE on February 12, 2024, which had informed Concord Medical that it was below compliance standards due to the trading price of its American Depositary Shares. With this latest update, Concord Medical has successfully addressed the compliance issue and is no longer considered below the NYSE Minimum Price Requirement.
Concord Medical (NYSE: CCM) announced plans to change the ADS Ratio of its American depositary shares (ADS) from 1 ADS representing 3 Class A ordinary shares to 1 ADS representing 30 Class A ordinary shares. This change is expected to be effective on July 30, 2024. The ADS holders must surrender and exchange every 10 existing ADSs for 1 new ADS. JPMorgan Chase Bank will manage the exchange process. No fractional new ADSs will be issued; fractional entitlements will be sold, and proceeds will be distributed to ADS holders. This ratio change is anticipated to proportionally increase the ADS trading price, but cannot guarantee it will be ten times the previous trading price.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Concord Medical Services Holdings Limited (NYSE: CCM) announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2022. This report is accessible on both Concord Medical's investor relations website and the SEC's website. Concord Medical specializes in oncology services, providing a full cycle of cancer diagnosis, treatment, education, and prevention via a network of radiotherapy and diagnostic imaging centers in China. The company emphasizes the deployment of advanced technology, including proton therapy systems, to enhance cancer care quality and accessibility. Shareholders can request a hard copy of the report free of charge.
Concord Medical Services Holdings Limited (NYSE: CCM) will hold its 2022 annual general meeting of shareholders on December 30, 2022, at 10:00 a.m. Beijing Time. The meeting will take place at the Global Trade Center in Beijing, and the shareholder record date is November 30, 2022. No proposals will be submitted for approval, as the meeting aims to facilitate discussions between shareholders and management. Additionally, the Company’s annual report on Form 20-F for the fiscal year ending December 31, 2021, is accessible on its investor relations website.